This page covers Drugs in ENT thesis topics across otology and audiology, rhinology, laryngology and airway disorders, head and neck surgery, and paediatric ENT for MS Otorhinolaryngology candidates. The emphasis is on ENT pharmacotherapy research topics that can be completed within one thesis period using routinely prescribed topical and systemic medications, validated symptom scores, audiological or endoscopic findings, microbiology where clinically indicated, and short-term clinical or perioperative outcomes. A shortlisted question should then be converted into a focused MS ENT drug-therapy protocol and a submission-ready MS Otorhinolaryngology synopsis.
Last reviewed and updated: September 2026 · 2026–27 admissions
Not the ENT subspeciality you need? Drugs in ent is one section of our full ENT collection — the hub page lists every subspeciality, each with its own free topic list. Updated September 2026.
Browse all ENT Thesis Topics →📌 Updated for 2026–2027 MS Otorhinolaryngology Drugs in ENT admissions
The research framework was reviewed for topical ear therapy, corticosteroids in sudden hearing loss, allergic-rhinitis and chronic-rhinosinusitis pharmacotherapy, laryngopharyngeal reflux treatment, perioperative medication, antibiotic stewardship and paediatric ENT drug use.
Select Generate Protocol → beside any title in the list above and receive a submission-ready document built around that topic, containing all eighteen components:
Already have your thesis title?
Generate the full drugs in ent protocol directly — objectives, methodology, sample size, statistics, timeline, references and annexures.
Generate your protocolAlongside drugs in ent protocols and synopses, support is also available for departmental presentations, journal club presentations, ethics committee presentations, and posters and oral presentations for medical conferences — for postgraduate residents, board trainees and research scholars across India and the GCC. Prepared by a practising doctor with long experience in medical publishing and thesis supervision.
Enquire on WhatsApp →Drugs in ent research outside India
The topics above work as research questions anywhere — what changes is the document the institution expects, and who approves it before data collection begins. The Gulf equivalent of an Indian synopsis is the drugs in ent research proposal submitted to an institutional review board, and it ordinarily carries three sections an Indian synopsis does not: a Gantt chart, a budget and resources section, and a Declaration of Helsinki statement.
Board and residency programmes — country by country
Saudi Arabia — SCFHS and the Saudi Board. Residency and fellowship training under the Saudi Commission for Health Specialties includes a research project with a set timeline, and the drugs in ent research proposal is the document prepared at the outset and cleared by the institutional review board before recruitment starts.
United Arab Emirates — DHA, DOH Abu Dhabi and MOHAP. Residents training in Dubai, Abu Dhabi and the northern emirates prepare a drugs in ent research protocol for their programme and submit it for institutional review board approval before any data are collected.
Qatar — DHP (formerly QCHP) and Hamad Medical Corporation. A drugs in ent IRB proposal is reviewed before recruitment, with the ethics section written to the institution's own template rather than a generic one.
Bahrain — NHRA. Trainees turning drugs in ent research topics into a project need the proposal cleared by their institutional research and ethics committee before fieldwork begins.
Oman — OMSB. Residency programmes under the Oman Medical Specialty Board include a research component, and the drugs in ent research proposal is the document assessed at the start of it.
Kuwait — KIMS. A drugs in ent study protocol goes to the institutional committee for approval before the project begins.
Arab Board programmes across the region. The Arab Board carries its own research requirement irrespective of the host country, and the drugs in ent proposal follows the same structure throughout.
Postgraduate degrees — Malaysia, the Gulf and beyond
Malaysia — MMed, the National Medical Research Register and MREC. A drugs in ent dissertation proposal for a Master of Medicine programme carried out in a Ministry of Health facility must be registered on the NMRR and approved by the Medical Research and Ethics Committee before the study begins, and the guidance asks for submission four to six months ahead of data collection. Every investigator on the study team registers on the NMRR as well, so the methodology, ethics and team sections are written in far more detail than an Indian synopsis requires.
PhD and Master's candidates elsewhere. University programmes generally require a full drugs in ent research proposal of roughly 6,000 to 10,000 words, with an extended literature review, a theoretical framework and a detailed methodology chapter.
PhD and MMed proposals are written individually by a medical doctor and revised until the supervisor accepts them. They are not produced by the automated protocol generator.
Enquire about a drugs in ent PhD or MMed proposal →🔥 Trending research areas in Drugs in ENT for 2026–27
Current ENT pharmacotherapy research increasingly focuses on targeted treatment, route-specific therapy, antimicrobial stewardship and clinically meaningful short-term outcomes rather than simple prescription comparisons.
A Drugs in ENT protocol must define the ENT diagnosis, baseline disease severity, medication, formulation, route, dose, frequency, duration, previous treatment, co-interventions and the exact time at which response is measured. A comparison of two drugs is difficult to interpret if one group receives treatment later, has more severe disease or has already failed another regimen.
Confounding by indication must be anticipated. In routine practice, systemic corticosteroids, intratympanic steroids, broad-spectrum antibiotics, combination therapy or prolonged treatment are often given to patients with more severe or refractory disease. An observational comparison can therefore make intensive therapy appear less effective simply because it was prescribed to a more difficult clinical group.
Treatment response must be defined before analysis. Otorrhoea control, Sino-Nasal Outcome Test scores, hearing improvement, vertigo control, reduction in polyp grade, pain relief, surgical-site infection and early airway response are different endpoints. The protocol should prespecify one primary outcome, its measurement method and the clinically appropriate assessment interval.
A Drugs in ENT synopsis can state that the study will compare or correlate treatment with symptom control, audiological improvement, endoscopic response, microbiological findings or postoperative recovery. The full protocol must convert these aims into reproducible definitions for drug exposure, dose, route, duration, adherence, baseline severity, permitted co-treatment, rescue treatment, adverse effects and outcome timing.
For antibiotic studies, culture collection should occur before or as close as possible to the start of antimicrobial therapy when clinically appropriate. For sudden sensorineural hearing loss, time from symptom onset to corticosteroid treatment and the audiometric definition of recovery should be fixed. For allergic rhinitis or chronic rhinosinusitis, symptom and endoscopic outcomes should be measured with the same instrument at baseline and follow-up.
Sample size should follow the primary outcome. A comparative drug study requires an expected difference in symptom score, hearing recovery, bleeding control or another prespecified endpoint; a prescription-pattern study requires an expected prevalence and desired precision; and an antimicrobial-resistance study needs enough culture-positive cases for meaningful analysis.
Baseline severity must be handled analytically. Patients receiving stronger or combination therapy may begin with worse symptoms, larger polyps, greater hearing loss, more extensive infection or higher surgical risk. Unadjusted post-treatment comparisons can therefore be misleading. Where possible, baseline values should be recorded and change from baseline or adjusted group comparisons should be used.
Repeated audiograms, symptom scores or endoscopic assessments from one patient are correlated observations and should not be treated as independent cases. Multiple drug comparisons increase false-positive risk and should be prespecified. Observational studies should describe association rather than imply causal superiority when treatment allocation was determined by the treating clinician rather than randomisation.
Choose a common ENT condition for which the medication is already used routinely and the response can be measured within a short, predefined interval. Otomycosis, active chronic otitis media, allergic rhinitis, chronic rhinosinusitis, sudden sensorineural hearing loss, epistaxis, deep neck infection and postoperative analgesia often provide practical datasets. Avoid a topic that depends on an expensive drug used in only a few patients unless adequate case volume is already established.
Suitable designs include descriptive prescription audits, analytical cross-sectional studies, comparative observational studies, prospective cohorts, case-control studies and randomised comparative studies when ethically and practically appropriate. If the treating clinician chooses the medication according to disease severity, the project remains observational even when two treatment groups are compared.
Settle the diagnosis, medication, dose, route, duration, baseline severity measure, previous therapy, permitted co-interventions, primary endpoint, assessment interval, rescue-treatment definition and adverse-effect monitoring. Also decide whether treatment is allocated by routine clinical judgement or by a research protocol because that distinction determines the study design and interpretation.
Yes, but the result should be interpreted as an observational comparison. The two groups may differ in age, baseline severity, previous treatment, contraindications, adherence or clinician preference. These differences can influence outcome independently of the drug itself. Baseline comparability and clinically important confounders should therefore be recorded and adjusted where appropriate.
The synopsis is the concise institutional submission describing the pharmacotherapy question, objectives, design and broad methods. The protocol is the operational document that fixes the drug regimen, dose, route, duration, baseline assessment, co-treatment, adherence, rescue therapy, adverse events, outcome definition, assessment timing, confounders and statistical analysis.
Patients should not receive an unnecessary antibiotic, systemic corticosteroid, sedative, ototoxic medication or other drug solely to create a thesis comparison group. Treatment needed urgently for sudden sensorineural hearing loss, severe infection, airway compromise or haemorrhage should never be delayed for recruitment or baseline research measurements. Drug dose and duration should remain within accepted clinical practice unless a separately approved interventional protocol justifies otherwise.
Prospective participants should provide informed consent, with guardian consent and age-appropriate assent for paediatric participants according to institutional policy. Adverse effects, allergy, ototoxicity, steroid complications, excessive sedation, gastrointestinal or renal effects of analgesics and clinically significant treatment failure should have predefined management and escalation pathways. Retrospective prescription audits may qualify for an ethics-approved waiver of individual consent when permitted by the institution.
The sharpest error is confounding by indication: assuming that outcome differences between routinely treated groups are caused by the drug while ignoring why the clinician selected that treatment. More severe or refractory patients often receive systemic therapy, combination treatment, broader antibiotics or intratympanic rescue treatment, so their outcome cannot be compared fairly with milder cases without considering baseline severity.
The protocol should therefore record the indication, pretreatment severity, prior medication and timing of therapy before outcome assessment. A second common error is measuring response at different intervals in the two groups. All groups should use the same prespecified outcome definition and clinically appropriate follow-up window.
An MS Otorhinolaryngology thesis is usually a focused residency dissertation evaluating one commonly used drug, regimen, prescribing practice or short-term response that can be completed within one training period. A PhD project may involve pharmacogenomics, novel drug delivery, biologic-response biomarkers, multicentre antimicrobial surveillance, health economics or larger pragmatic clinical trials.
Residents outside the Indian MS pathway should verify dissertation or research requirements with the relevant training authority and institution. Drug governance, interventional-study approval, paediatric prescribing, adverse-event reporting, ethics review, supervision and completion milestones should follow the applicable local programme.
Register after confirming case volume, the medication and regimen, baseline severity measure, treatment-allocation pathway, primary endpoint and follow-up interval, but before prospective research-specific data collection begins. For retrospective work, fix the study period, drug-exposure definitions and outcome criteria before reviewing treatment results so that cases are not selected according to response already known.
Found a topic that fits your department?
Generate its full protocol — objectives, methodology, sample size, statistics, timeline, references and annexures — in editable format.
Generate your protocol